ArticleJournal of clinical microbiology2021
Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers.
Open access · greenAbstract readComparative Study
In one paragraph
Article in Journal of clinical microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 2 syntheses or guidelines pooled it, 197 citations in OpenAlex.
- Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews · 2022Pooled it
- Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.JMIR public health and surveillance · 2021Pooled it
- ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.Scientific reports · 2023Trial
- Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.JAMA network open · 2021Trial
- SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals.The Journal of clinical investigation · 2021Trial
- Neutralizing Antibody Response Dynamics in COVID-19: Insights from Healthy Vaccinees, Breakthrough Infections, and Critically Ill Patients.Tropical medicine and infectious disease · 2026Article
- Sociodemographic characteristics of SARS-CoV-2 serosurveillance studies with diverse recruitment strategies, Canada, 2020 to 2023.BMC public health · 2025Article
- A Surrogate Enzyme-Linked Immunosorbent Assay to Select High-Titer Human Convalescent Plasma for Treating Immunocompromised Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.The Journal of infectious diseases · 2025Article
- Convalescent plasma therapy for COVID-19 - Donor selection strategies and establishment of a plasma bank.New microbes and new infections · 2024Article
- Assessing the performance of commercial serological tests for SARS-CoV-2 diagnosis.IJID regions · 2024Article
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response in adults with predominantly antibody deficiency.The journal of allergy and clinical immunology. Global · 2024Article
- SARS-CoV-2 infection prevalence and associated factors among primary healthcare workers in France after the third COVID-19 wave.Scientific reports · 2024Article
- Omicron Infections in Vaccinated Pediatric Solid Organ Transplant Recipients.Journal of the Pediatric Infectious Diseases Society · 2024Article
- Anti-spike antibody durability after SARS-CoV-2 vaccination in adolescent solid organ transplant recipients.Pediatric transplantation · 2024Observational
- Faradaic Impedimetric Immunosensor for Label-Free Point-of-Care Detection of COVID-19 Antibodies Using Gold-Interdigitated Electrode Array.Biosensors · 2023Article
- A bead-based multiplex assay covering all coronaviruses pathogenic for humans for sensitive and specific surveillance of SARS-CoV-2 humoral immunity.Scientific reports · 2023Article
- Association of SARS-CoV-2 infection with physical activity domains and types.Scientific reports · 2023Article
- Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time.Nature communications · 2023Article
- Clinical outcome and humoral immune responses of β-thalassemia major patients with severe iron overload to SARS-CoV-2 infection and vaccination: a prospective cohort study.EClinicalMedicine · 2023Article
- SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines.Human vaccines & immunotherapeutics · 2023Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
26 authors at 2 institutions in 1 country.
Eshan U PatelDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-2174-5004
Evan M BlochDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
William ClarkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Yu-Hsiang HsiehDepartment of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Denali BoonDepartment of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Yolanda EbyDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Reinaldo E FernandezDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Owen R BakerDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, USA.
Morgan KerulyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Charles S KirbyDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ethan KlockDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Kirsten LittlefieldDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Jernelle MillerDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Haley A SchmidtDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Philip SullivanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Estelle Piwowar-ManningDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ruchee ShresthaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Andrew D ReddDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Richard E RothmanDepartment of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
David SullivanDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Shmuel ShohamDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Arturo CasadevallDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-9402-9167
Thomas C QuinnDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Andrew PekoszDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0003-3248-1761
Aaron A R Tobian *Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Oliver Laeyendecker *Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA olaeyen1@jhmi.edu.ORCID 0000-0002-6429-4760
Johns Hopkins University · USNational Institutes of Health · US
Funding
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2MNIDA Epidemiology Training Program: Johns Hopkins UniversityT32DA007292 · NIDA · JOHNS HOPKINS UNIVERSITY · PI RENEE M. JOHNSON, Brion S Maher · 1993 to 2026
$17.7MHIV Prevention Trials Network: Network LaboratoryU01AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2006 to 2010
$16.5MSynergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4MJohns Hopkins HIV Epidemiology and Prevention Sciences Training ProgramT32AI102623 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta · 2013 to 2026
$5.3MConjugate vaccines for prevention and treatment of cryptococcosis - COVID-19 Revision SupplementR01AI152078 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2020 to 2024
$5.1MUnlocking the Potential of HIV-Infected Deceased Donors for Organ TransplantationR01AI120938 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2016 to 2021
$4.3MINTERNATIONAL STUDIES ON THE ACQUIRED IMMUNODEFICIENCY SYNDROMEZ01AI000361 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI QUINN, THOMAS · 1985 to 2008
$3.1MPenile Microbiome, Inflammation and HIV Susceptibility During Sexual Debut and Maturation Among Male AdolescentsR01AI128779 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2017 to 2020
$2.1MInnate NKT Cells in HIV InfectionR01AI052731 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NIXON, DOUGLAS F · 2002 to 2006
$2.1MThe Malaria Transfusion Risk (MATRix) StudyK23HL151826 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BLOCH, EVAN MARTIN · 2020 to 2024
$882kLONGITUDINAL STUDY OF DEPRESSION IN LUNG CANCERR01NR005228 · NINR · UNIVERSITY OF SOUTH FLORIDA · PI WEITZNER, MICHAEL A · 1999 to 2002
$550kIntramural NIH HHS Z01 AI000361NHLBI NIH HHS K23 HL151826NHLBI NIH HHS R01 HL059842NIAID NIH HHS HHSN272201400007CNIAID NIH HHS R01 AI052731NIAID NIH HHS R01 AI120938NIAID NIH HHS R01 AI128779NIAID NIH HHS R01 AI152078NIAID NIH HHS T32 AI102623NIAID NIH HHS U01 AI068613NIAID NIH HHS UM1 AI068613NIDA NIH HHS T32 DA007292NINR NIH HHS R01 NR005228
Abstract
Accurate serological assays to detect antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to characterize the epidemiology of SARS-CoV-2 infection and identify potential candidates for coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) donation. This study compared the performances of commercial enzyme immunoassays (EIAs) with respect to detection of IgG or total antibodies to SARS-CoV-2 and neutralizing antibodies (nAbs). The diagnostic accuracy of five commercially available EIAs (Abbott, Euroimmun, EDI, ImmunoDiagnostics, and Roche) for detection of IgG or total antibodies to SARS-CoV-2 was evaluated using cross-sectional samples from potential CCP donors who had prior molecular confirmation of SARS-CoV-2 infection (
Indexed as
Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 Serological TestingCross-Sectional StudiesHumansImmune SeraImmunoenzyme TechniquesImmunoglobulin GNeutralization TestsSARS-CoV-2Sensitivity and SpecificityAntibodies, NeutralizingAntibodies, ViralImmune SeraImmunoglobulin Gconvalescent plasmaCOVID-19neutralizing titersSARS-CoV-2serologic assays
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.